Akero Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview

Akero Therapeutics

31/10/2023 18:34

* Akero Therapeutics Inc  AKRO.OQ   AKRO.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Akero Therapeutics
Inc is
for a loss of 68 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akero
Therapeutics Inc is $40​, above​ its last closing price
of $11.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.62       -0.63      -0.60     Beat    4.5
 Mar. 31 2023  -0.66       -0.67      -0.55     Beat    18.2
 Dec. 31 2022  -0.81       -0.80      -0.49     Beat    38.6​
 Sep. 30 2022  -0.71       -0.74      -0.92     Missed  -24.7
 ​​Jun.        -0.79       -0.86      -0.77     Beat    10
 30 2022                                                
 Mar. 31 2022  -0.82       -0.80      -0.74     Beat    7.3​
 Dec. 31 2021  -0.83       -0.82      -0.93     Missed  -13.6
 Sep. 30 2021  -0.91       -0.91      -0.70     Beat    23.1
 This summary was machine generated October 31 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated